版本:
中国

BRIEF-Allergan and Paratek announce positive results from two phase 3 trials of sarecycline

March 27 Allergan Plc:

* Allergan and Paratek announce positive results from two phase 3 trials of sarecycline for the treatment of moderate to severe acne

* Allergan Plc - plans to file a new drug application (NDA) to U.S. Food & drug administration (fda) in second half of this year

* On track for FDA submission in second half of 2017

* Sarecycline was statistically significantly superior to placebo with respect to primary efficacy endpoints Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐